Quetiron 200mg 30 tablets — Made in Ukraine — Free Delivery

Product description

Quetiron® Asino tablets are prescribed for the following indications:

• Schizophrenia.
• Bipolar disorder, including manic episodes associated with bipolar disorders; major depressive episodes associated with bipolar disorder.
• Prevention of relapse in patients with bipolar disorder treated with quetiapine for manic attacks.

Composition

active ingredient: quetiapine 1 tablet contains quetiapine fumarate in terms of quetiapine 25 mg, 100 mg or 200 mg

excipients: lactose monohydrate, calcium hydrogen phosphate dihydrate, microcrystalline cellulose, sodium starch glycolate, povidone, magnesium stearate shell: Opadry II White (polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide E 171), Opadry IIYellow (Quetiron 100) (polyethylene glycol, polyvinyl alcohol , talc, titanium dioxide E 171, quinoline yellow E 104, iron oxide yellow E 172, iron oxide red E 172).

Contraindications.

Hypersensitivity to the components of the preparation.

Simultaneous use of cytochrome P450 3A4 inhibitors, such as HIV protease inhibitors, azole antifungals, erythromycin, clarithromycin and nefazodone (see section "Interaction with other preparations and other forms of interaction").

Dosage and administration

There are different dosages for each indication. The dose of the preparation and the duration of the course of treatment are determined by the doctor individually for each patient, depending on the indications and severity of the disease.

For oral use.

Quetiapine can be taken with or without food.

Adults.

Course treatment of schizophrenia.

Quetiapine should be taken twice a day.

In the first 4 days of therapy, the daily dose is: 1st day - 50 mg, 2nd day - 100 mg, 3rd day - 200 mg, 4th day - 300 mg. Starting from the fourth day, increase the dose until the desired clinical effect is achieved (ranging from 300 to 450 mg / day). Depending on the clinical efficacy and tolerability of the preparation, the daily dose of Kvetiron can be from 150 mg to 750 mg.

The maximum daily dose of Kvetiron for the treatment of schizophrenia is 750 mg.

Course treatment of manic episodes associated with bipolar disorders.

Quetiapine should be taken twice a day.

The daily dose in the first 4 days of treatment is: 1st day - 100 mg, 2nd day - 200 mg, 3rd day - 300 mg, 4th day - 400 mg. In the future, increase the dose (but not more than 200 mg per day) to 800 mg / day, starting from the 6th day of treatment. Depending on the clinical efficacy and tolerability of the preparation, the dose can be from 200 to 800 mg / day. The usual effective dose is in the range of 400 to 800 mg per day.

The maximum daily dose of Quetiron for the treatment of manic episodes is 800 mg.

Treatment of depressive episodes associated with bipolar disorder.

Quetiapine should be taken once a day at bedtime.

The daily dose in the first 4 days of treatment is: 1st day - 50 mg, 2nd day - 100 mg, 3rd day - 200 mg, 4th day - 300 mg. The recommended daily dose is 300 mg. It is known that in clinical studies no additional benefit was observed in the 600 mg group compared to the 300 mg group. A dose of 600 mg may be effective in some patients. Clinical studies show that for individual patients in the event of problems associated with preparation intolerance, a dose reduction to a minimum of 200 mg can be considered. Treatment of depressive episodes associated with bipolar disorder should be initiated by a physician experienced in the treatment of bipolar disorder.

Prevention of relapse in patients with bipolar disorder.

To prevent further manic, depressive or mixed episodes in bipolar disorder, patients who have responded to quetiapine in the emergency treatment of bipolar disorder should continue treatment at the same dose. The dose can be adjusted depending on the clinical response and tolerability of each individual patient within the range of a daily dose of 300 mg to 800 mg, administered 2 times a day. It is important that the lowest effective dose be used for maintenance therapy.

Elderly patients.

In elderly patients, quetiapine, like other antipsychotics, should be administered with caution, especially at the beginning of treatment. A slower titration of the dose of quetiapine may be necessary, and the daily therapeutic dose should be lower than that used in young patients, depending on the clinical response and tolerability of treatment in each individual patient. The mean clearance of quetiapine was reduced by 30-50% in elderly patients compared to younger patients.

Efficacy and safety have not been evaluated in patients over 65 years of age with depressive episodes in bipolar disorder.

Impaired liver and kidney function.

Dose adjustment is not necessary in patients with renal insufficiency.

Quetiapine is actively metabolized in the liver, so patients with hepatic insufficiency should be used with caution, especially during the initial period of treatment.

Patients with impaired liver function should start with a dose of 25 mg/day. The dose is increased daily by 25-50 mg / day until an effective dose is reached, depending on the clinical response and the patient's tolerance to the preparation.